Order a Test

We make it easy to order our comprehensive genomic profiling tests for your advanced cancer patients.

Jump to
Overview

Ordering Overview

Foundation Medicine tests must be ordered by a licensed physician. We offer multiple ways to order our tests:

  • Electronic Medical Record (EMR) Systems: our integrations with EMR systems, like Epic® and OncoEMR®, will allow you to place an order for a test directly through your practice's EMR system if enabled
  • Foundation Medicine’s Online Portal: login or sign up for an online account
  • Email or Fax: download or print our Test Requisition Form. Completed forms and associated attachments can be submitted via email to client.services@foundationmedicine.com or via fax to +1 (617) 418-2290

If sending a solid tumor specimen, Foundation Medicine can complete the specimen retrieval process if requested on the order form (complete pathology lab information must be provided). If sending peripheral blood or bone marrow aspirate, please order the appropriate test kit with the form below to your practice and follow the specimen preparation instructions for liquid specimens.

International Customers: To order, please visit rochefoundationmedicine.com or call +1 (888) 988-3639.

Ordering Resources

How to Order

How to Order a Foundation Medicine Test

If you will be sending an FFPE block or unstained slides to Foundation Medicine for testing with FoundationOne®CDx or FoundationOne®Heme, please follow the instructions below:

  1. Place a test order through your EMR system if enabled or order online by logging in or signing-up for a Foundation Medicine account. Orders can also be submitted via email or fax using our Test Requisition Form.
  2. Complete the order form, provide any required attachments including Advanced Beneficiary Notice if needed, and submit. Some pathology labs require patient consent prior to releasing a specimen for testing, so providing us with a completed Specimen Release Consent Form up front can help avoid potential order delays.
  3. Foundation Medicine will contact the pathologist if requested during the ordering process with instructions for sample procurement and shipment. If you will be arranging for specimen shipment yourself, please do so after submitting the order form. To request a Specimen Shipping Kit please contact client services or fill out our Order a Shipping Kit form below.
  4. You will receive online or printed results typically 8 days or less from receipt of specimen for FoundationOne CDx.

 

We know how important efficiency is for your clinical workflow. That’s why we’re partnering with EMR systems like Epic and OncoEMR to integrate our comprehensive genomic profiling (CGP) tests and our other testing services into your practices’ workflow. Once enabled, our EMR integrations allow providers to place orders for our CGP tests and receive and view test results directly within their existing workflow.

To learn more about our EMR integrations, please contact your Commercial Program Manager or reach out to our Client Services team at client.services@foundationmedicine.com or +1 (888) 988-3639.

Learn more about how online ordering, digital reporting, and our mobile application can help transform your genomic testing workflow.

Learn More About Online Ordering & Report Integrations

Foundation Medicine is committed to helping patients access our testing services. Some commercial health plans such as Cigna and many BlueCross BlueShield plans offer coverage for Foundation Medicine testing services. Medicare covers FoundationOne CDx, FoundationOne Liquid CDx, and FoundationOne Heme for qualifying patients. FoundationOne CDx is also covered by TRICARE for qualifying patients. FoundationOne®Heme has limited commercial health plan coverage at this time.

Learn More About Billing & Financial Assistance
Additional Ordering Options

Additional Ordering Options

Mobile Phlebotomy

Foundation Medicine offers in-home blood draw services through a mobile phlebotomy vendor to support broader access to FoundationOne Liquid CDx and FoundationOne Heme, at no additional cost. Mobile phlebotomy can be requested during the online ordering process or on our test requisition form. If requested, we will schedule a phlebotomist appointment directly with the patient and ship a kit to their home.

Resources

Order a Kit

Order Foundation Medicine Specimen Shipping Kits to your practice.

Answers to Common Questions

View all Provider FAQs

Additional Notes

FoundationOne Heme was developed and its performance characteristics determined by Foundation Medicine. It has not been cleared or approved by the U.S. Food and Drug Administration. For more information on this laboratory developed test please see the Technical Specifications at foundationmedicine.com/f1h.

Important Safety Information

Select

FoundationOne CDx and FoundationOne Liquid CDx

FoundationOne®CDx and FoundationOne®Liquid CDx are qualitative next-generation sequencing based in vitro diagnostic tests for advanced cancer patients with solid tumors and are for prescription use only. FoundationOne CDx utilizes FFPE tissue and analyzes 324 genes as well as genomic signatures. FoundationOne Liquid CDx analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes. The tests are companion diagnostics to identify patients who may benefit from treatment with specific therapies in accordance with the therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the tests does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy for testing with FoundationOne CDx when archival tissue is not available which may pose a risk. When considering eligibility for ROZLYTREK® based on the detection of NTRK1/2/3 and ROS1 fusions, or for TEPMETKO® based on the detection of MET SNVs and indels that lead to MET exon 14 skipping, testing using plasma specimens is only appropriate for patients for whom tumor tissue is not available for testing. Patients who are tested with FoundationOne Liquid CDx and are negative for other companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com and www.F1LCDxLabel.com.